Allianz Asset Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Allianz Asset Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,200	Closed	-$234K	–	2086
2025 Q3	$234K	Buy	+15,200	New	+$199K	﹤0.01%	1941
2025 Q1	–	Sell	-19,500	Closed	-$258K	–	2347
2024 Q4	$258K	Hold	19,500	–	–	﹤0.01%	2043
2024 Q3	$375K	Sell	19,500 -10,800	-36%	-$223K	﹤0.01%	1930
2024 Q2	$622K	Hold	30,300	–	–	﹤0.01%	1761
2024 Q1	$721K	Sell	30,300 -700	-2%	-$15.6K	﹤0.01%	1508
2023 Q4	$670K	Buy	+31,000	New	+$477K	﹤0.01%	1752
2023 Q3	–	Sell	-26,800	Closed	-$561K	–	2257
2023 Q2	$561K	Buy	26,800 +6,800	+34%	+$142K	﹤0.01%	1702
2023 Q1	$422K	Buy	20,000 +4,000	+25%	+$99.5K	﹤0.01%	1933
2022 Q4	$407K	Hold	16,000	–	–	﹤0.01%	1767
2022 Q3	$384K	Sell	16,000 -92,655	-85%	-$2.08M	﹤0.01%	1568
2022 Q2	$2.09M	Buy	108,655 +9,145	+9%	+$152K	﹤0.01%	1411
2022 Q1	$1.73M	Buy	99,510 +25,280	+34%	+$426K	﹤0.01%	1640
2021 Q4	$1.62M	Buy	+74,230	New	+$1.37M	﹤0.01%	1697

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Allianz Asset Management's SNDX Position: Q4 2025 in Review

Allianz Asset Management sold out of Syndax Pharmaceuticals (SNDX) in Q4 2025, closing a stake of 15,200 shares — an estimated $234K sold.

Allianz Asset Management first reported a position in SNDX in Q4 2021 and held it in 13 quarters. The position peaked at $2.09M in Q2 2022. 230 funds tracked by Wall St. Rank hold SNDX as of Q4 2025.

Allianz Asset Management reported no remaining Syndax Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Allianz Asset Management sold 15,200 Syndax Pharmaceuticals shares in Q4 2025, an estimated $234K.
Allianz Asset Management first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 13 quarters.
Allianz Asset Management's Syndax Pharmaceuticals position peaked at $2.09M in Q2 2022.
230 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q4 2025.

Based on Allianz Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.